Financial Results for the Fiscal
Year Ended March 31, 2024

Tokyo Stock Exchange Standard Market
Securities Code: 7775

Innovation for the Future of Medical❏ Table of Contents
Summary of Financial Results for
the Fiscal Year Ended March 31, 2024
Forecast for the Fiscal Year Ending
March 31, 2024
Strategy for Growth1

Innovation for the Future of Medical

Summary of Financial Results for
the Fiscal Year Ended March 31, 2024

2

Innovation for the Future of Medical❏ Financial Results(Unit: million yen)
Fiscal year ended
March 31, 2023

Fiscal year ended
March 31, 2024

YoYNet sales

9,137

9,750

Gross profit

3,530(Gross margin)

3,981(38.6%)（40,8%）+12.8%

SG&A expenses

2,475(SG&A ratio)

2,539(27.1%)（26.0%）+2.6%

Operating profit

1,054

1,442

+36.8%

Ordinary profit

1,053(Ordinary profit ratio)

1,450(11.5%)（14.9%）+37.6%

Profit712

988+38.8%

¥20.0

¥21.0

―

Dividend per share

+6.7%

3

Innovation for the Future of Medical

Sales by Segment (Year-on-Year Comparison)
Steady sales of mainstay products
and expansion of AMY adoption(Unit: million yen)

Fiscal year ended
March 31, 2023
Total

Component
ratio

Fiscal year ended
March 31, 2024
Total

YoY

Component
ratio

Suction device

5,820

63.7%

6,190

63.5%

+6.4%

(QinPot )(FitFix+BYRON)(2,303)(3,517)(25.2%)(38.5%)(2,489)(3,701)(25.5%)(38.0%)(+8.1%)(+5.2%)

Infusion pump

2,008

22.0%

2,104

21.6%

+4.8%

(PCA Set+AMY)(1,725)(18.9%)(1,826)(18.7%)(+5.9%)

Electric Power Operated
Pump

248

2.7%

262

2.7%

+5.5%

Hand Washing Equipment

585

6.4%

678

7.0% +16.0%Other473

5.2%

513

5.2%

+8.3%

Total

9,137

100.0%

9,750

100.0%+6.7%
4

Innovation for the Future of Medical❏ Analysis of Variance of Ordinary Profit for the Fiscal Year
Ended March 2024 (YoY)
Steady increase in gross margin
Increase in profits despite incorporating
measures to boost personnel investment

FY2023
2023年3月期

55
Increase in SG&A expenses

Increase in other costs（No impact from previous period’s entries)

1,053

Increase in grossmargin due to highersales volume370

One-time write-downs due to slow
moving inventory

172

90(Unit: million yen)

1,450

FY20242024年3月期

5Innovation for the Future of Medical

Forecast for the Fiscal Year Ending
March 31, 2025

6

Innovation for the Future of Medical❏ Forecasts and Dividends for the Fiscal Year Ending March 31, 2025
(Unit: million yen)

Fiscal year ended
March 31, 2024
(Actual)Fiscal year ending
March 31, 2025
(Forecast)

YoY

Net sales

9,750

10,100+3.6%

Operating profit

1,442

1,500

+4.0%

Ordinary profit

1,450

1,500

(Ordinary profit ratio)（14.9%）（14.9%）+3.4%

Profit988

1,030+4.2%

Dividend per share

¥21.0

¥22.0

―

Dividend payout ratio

61.0%

61.4%

―

7

Innovation for the Future of Medical❏ Financial Results

Ordinary profit
500 Net sales
500
8,399 8,585
8,406 8,523
500
1,714
500
1,504
1,245
500
1,210
1,246
500
1,012
859
851
500
500
500
500 2017.03 2018.03 2019.03 2020.03(Unit: million yen)

Profit9,750

10,100

9,137
8,540
7,861

1,152
957
831
675

2021.032022.03

1,053

1,450

1,500

988

1,030

712

2023.032024.032025.03(Forecast)8

Innovation for the Future of Medical

Strategy for Growth9Innovation for the Future of Medical

Mid-to-long Term Strategy Overview (4 Growth Pillars)
1. Replacement of existing products
2. Product development and launch
complementing existing businesses
3. Dominating the overseas market with AMY

4. Market introduction for new fields and markets

10Innovation for the Future of Medical❏ Mid-to-long Term Strategy Overview and Growth Strategy

Replacement of existing products
Improved
BYRON

FitFixSyrinjector

Patent number 7269851, etc.

Market trials underway at multiple medical institutions

Balloonjector

AMY

Patent number 6726166, etc.

Expanding sales and profits for acute phase and home careapplications
Main unit

Patents expired
Controller

Built-in micropump

11

Innovation for the Future of Medical❏ Mid-to-long Term Strategy Overview and Growth Strategy
Product development and launch
complementing existing businesses

Suction device
business
Infusion pumpbusiness
Electric PowerOperated
Pump business

AMY
Deployment for chemotherapy(Anticancer drug administration)

Development of derivative products
from existing businesses

Other12

Innovation for the Future of Medical❏ Mid-to-long Term Strategy Overview and Growth Strategy
Entering the overseas market with AMY
Also sell highly original
products on overseas markets

State of progress
Acquisition of MDR
Planned for FY2024

AMY
Domestic
market scale¥6.0 billion

AMYOverseasmarket¥30.0 billion* Acquisition expected in early summer atearliest

Completed building organizationforclinical evaluation
to be conducted in Europe afteracquisition(Awaiting MDR acquisition)
13

Innovation for the Future of Medical

Launching major products in new fields and markets

Expansion into multiple domains
through the application of fundamental
micro-pump technology

Internal medicine fields

Insulin pump
(Diabetes treatment)Domestic market scale

Over ¥30.0 billion

Existingareas
14

Innovation for the Future of Medical

Product development research center (Izumi-shi, Osaka, Japan)

For inquiries regarding this material andinformation on IR, please contact the below.

DAIKEN MEDICAL CO.,LTD.

Finance & Accounting Department
TEL: 06-6231-9917
URL: https://www.daiken-iki.co.jp/ir (in Japanese)

Any forward-looking statements in this document, including figures andstrategies, are based on current assumptions and projections in light of theinformation currently available to us and are subject to risks anduncertainties. Actual results may differ from the forecasts due to variousfactors.
15